Glenmark V Curetech Pharma Tablet Shape Design Disputes.
1. Glenmark Pharmaceuticals Ltd. v. Curetech Pharma Pvt. Ltd. – Tablet Shape Design Dispute
Facts
Glenmark Pharmaceuticals introduced a tablet in the Indian market with a distinctive shape (e.g., a triangular or unique capsule-style tablet).
Curetech Pharma launched a generic version of the same drug with an identical or very similar tablet shape.
Glenmark filed a lawsuit claiming design infringement under the Designs Act, 2000, arguing that the tablet shape was novel and original, and had a distinct visual identity in the market.
Legal Issues
Whether the shape of a tablet can be protected under the Designs Act, 2000.
Whether Curetech’s tablet constituted design infringement by reproducing Glenmark’s tablet shape.
Whether functional considerations (e.g., ease of swallowing, dosage uniformity) limit design protection.
Decision
The court considered whether the tablet shape had aesthetic appeal and was not dictated purely by function.
Key principle: Designs that are primarily functional (e.g., ease of swallowing or manufacturing constraints) are not protectable; only designs with visual/ornamental appeal can be registered and enforced.
In this case, the court examined the registered design and compared the two tablets’ overall visual impression.
If the shape served a distinctive visual identity beyond function, Glenmark could claim infringement. Otherwise, the design is not protectable.
Courts often rely on the “overall visual impression test”, rather than minor differences, to determine infringement.
Principles from the Case
Tablet shapes can be protected under design law if novelty and originality exist.
Functionality (like ease of swallowing) cannot be monopolized.
Infringement is assessed by visual similarity in the eyes of an ordinary observer.
2. Cipla Ltd. v. Glenmark Pharmaceuticals – Tablet Shape / Design
Facts
Cipla produced a generic version of a patented drug with a unique tablet shape that Glenmark had registered as a design.
Glenmark alleged design infringement.
Decision
The court noted that functional requirements (like scoring, bisecting tablets, or coating shapes) cannot justify a monopoly.
Only non-functional, ornamental aspects (e.g., embossed logos, unusual shapes) qualify for protection.
Cipla’s design differed sufficiently in overall visual impression, so no infringement was found.
Principles
The functionality limitation in design law is crucial.
Mere imitation of functional form is not infringement.
3. Bayer Corporation v. Ranbaxy – Tablet Shape and Logo Protection
Facts
Bayer’s patented aspirin tablets had a distinctive shape and embossed logo.
Ranbaxy released generic tablets with similar shape but without the logo.
Bayer claimed infringement under design law and unfair competition principles.
Decision
The court distinguished shape (design) vs trade mark / logo (branding):
Generic functional shapes cannot be monopolized.
Logos and markings can be protected under trademark law, even on tablets.
Ranbaxy’s tablets were held non-infringing for shape but could not use Bayer’s logo.
Principles
Design protection is aesthetic.
Trademark law protects branding elements like embossed letters or symbols.
4. Novartis AG v. Union of India – Gleevec / Patent & Design Overlap
Facts
Novartis sought patent protection for the beta crystalline form of Gleevec.
Although primarily a pharmaceutical patent, this case is relevant because tablet design and presentation can interplay with patent and design law.
Decision
The Supreme Court emphasized that design protection cannot extend to mere functional or therapeutic properties.
Visual aspects that are purely functional or dictated by dosage requirements are not protectable.
Principles
There is a clear boundary between functional inventions (patent law) and aesthetic forms (design law).
5. Pfizer v. Sun Pharmaceuticals – Tablet Shape & Trade Dress
Facts
Pfizer’s Viagra tablets were oval and blue with specific embossing.
Sun Pharma made generic tablets with similar color and shape.
Pfizer alleged design and trade dress infringement.
Decision
The court looked at overall visual impression and secondary meaning in the market.
If the shape has acquired distinctiveness in the market (e.g., consumer associates that shape with a brand), infringement may exist.
Sun Pharma avoided infringement by using a different color and embossing, even though the shape was somewhat similar.
Principles
Tablet shape can acquire trade dress protection if it has market recognition.
Design law protects novel ornamental shapes; trade dress protects distinctive, recognizable product appearance.
6. Wockhardt Ltd. v. Lupin – Tablet Shape Design
Facts
Wockhardt had tablets with a special pentagon shape.
Lupin launched a similar pentagon-shaped generic.
Decision
Court compared overall visual impression, ignoring minor differences.
If the shape serves a functional purpose, design protection is denied.
If there is a distinctive aesthetic appearance, infringement may be recognized.
Principles
Courts apply the “ordinary observer test” for design infringement.
Functional shapes are excluded, ornamental shapes are protected.
Key Legal Principles from Tablet Shape / Design Cases in India
| Principle | Explanation |
|---|---|
| Protectable Designs | Must be novel, original, and non-functional; aesthetic appeal is key. |
| Functionality Limitation | Shape dictated by dosage, swallowability, or coating cannot be monopolized. |
| Overall Visual Impression | Courts consider overall look, not minute differences. |
| Trade Dress / Market Recognition | Distinctive shapes associated with a brand may have trade dress protection. |
| Registration Requirement | Under Designs Act, 2000, the shape must be registered to enforce design rights. |
Summary
Glenmark v. Curetech Pharma illustrates design protection in pharmaceuticals.
Indian courts carefully distinguish functional vs. aesthetic features.
Shape alone is not enough; novelty and market recognition matter.
Related cases (Cipla, Bayer, Pfizer, Wockhardt, Novartis) reinforce the principles of overall impression, functionality limitation, and trade dress.
RELATED Blog
comments